SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
JCI Insight. 2018 Aug 9;3(15):e98720. doi: 10.1172/jci.insight.98720. eCollection 2018 Aug 9.
JCI Insight. 2018.
PMID: 30089717
Free PMC article.